EP
CHRS icon

Elkfork Partners’s Coherus Oncology CHRS Stock Holding History

Elkfork Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$56K Hold
2,754
– – ﹤0.01% 984
2019
Q2 		$61K Hold
2,754
– – ﹤0.01% 994
2019
Q1 		$37K Buy
2,754
+578
+27% +$7.71K ﹤0.01% 995
2018
Q4 		$20K Buy
+2,176
New +$25.2K ﹤0.01% 977

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Elkfork Partners's CHRS Position: Q3 2019 in Review

Elkfork Partners held its Coherus Oncology (CHRS) position steady in Q3 2019 at 2,754 shares worth $56K. The position accounts for ﹤0.01% of the portfolio, ranked #984.

Elkfork Partners first reported a position in CHRS in Q4 2018 and has held it in 4 quarters since. The position peaked at $61K in Q2 2019. 167 funds tracked by Wall St. Rank hold CHRS as of Q3 2019.

  • Elkfork Partners held 2,754 shares of Coherus Oncology worth $56K as of Q3 2019.
  • Elkfork Partners left its Coherus Oncology share count unchanged in Q3 2019.
  • Coherus Oncology made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #984 holding.
  • Elkfork Partners first reported a position in Coherus Oncology in Q4 2018 and has held it in 4 quarters since.
  • Elkfork Partners's Coherus Oncology position peaked at $61K in Q2 2019.
  • 167 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.